News

Veristat and AOBiome Establish a Preferred Partnership To Support Ongoing & Impending Clinical Programs

June 19, 2017

SOUTHBOROUGH, MA –  June 19, 2017Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, have entered into a Preferred Provider Agreement (PPA). 

Read More

Veristat Congratulates TESARO on the FDA Approval of ZEJULA™

May 30, 2017

SOUTHBOROUGH, MA –  May 30, 2017 –   Veristat, a full service Clinical Research Organization (CRO), congratulates TESARO, Inc. on the approval of ZEJULA™.  

Read More

Veristat Acknowledged on Boston Business Journal’s “Fast 50” List for a Second Consecutive Year

May 15, 2017

Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts

Read More

Veristat Opens New Office in North Carolina Today

February 1, 2017

Veristat announced today the official opening of its new office in Morrisville, NC. 
Read More

Veristat Appoints James Roach, MD as Chief Medical Officer

November 7, 2016

Veristat Strengthens its Clinical Operations, Medical and Regulatory Affairs Offerings


SOUTHBOROUGH, MA – November 07, 2016 – Veristat announced that it has appointed James (Jim) Roach, MD, FACP, FCCP as its new Chief Medical Officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings.
Read More

Veristat Formalizes its Strategic Decision Consulting Services

November 1, 2016

SOUTHBOROUGH, MA –  November 01, 2016Veristat, a full service consultative Clinical Research Organization (CRO), announced today the formal launch of its Strategic Decision Consulting service offering to help pharmaceutical, biotechnology and medical device firms solve the unique and complex challenges they face throughout the development process.  

Read More

Veristat Strengthens Its Long-Standing Relationship with Aegerion Pharmaceuticals

September 20, 2016

Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.  Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.

Read More

Veristat Acknowledged for its Rapid Growth on the Inc. 5000 List of America’s Fastest-Growing Private Companies

August 17, 2016

Veristat Continues To Be Recognized for Its Positive Impact & Company Growth

SOUTHBOROUGH, MA – August 17, 2016Veristat announced today that it has been recognized once again by Inc. Magazine as one of America’s fastest-growing private companies. Veristat debuted on the list in 2015.

Read More

Veristat Article “Adaptive Designs- Recent Advancement in Clinical Trials” Published in “Journal of Bioanalysis & Biostatistics”

July 14, 2016

Two of Veristat’s statistical and adaptive design experts submitted a research paper which was published in the June 2016 issue of the Journal of Bioanalysis & Biostatistics.

Read More

Fueled by Growth, Veristat Continues Geographic Expansion in North Carolina

June 27, 2016

Accelerates Hiring & Plans to Open Office in Raleigh-Durham, North Carolina

 

Read More